FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 7880人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839946, encodeId=438a1839946b6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=新药进展 | 辉瑞口服新冠特效药Paxlovid获FDA批准，预防死亡效力高达89%, objectType=article, longId=292889, objectId=1127292889b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1127292889b8, replyNumber=0, likeNumber=78, createdTime=2022-06-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1127292889b8, moduleTitle=新药进展 | 辉瑞口服新冠特效药Paxlovid获FDA批准，预防死亡效力高达89%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1127292889b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839962, encodeId=a5ec183996278, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药, objectType=article, longId=301203, objectId=bed4301203e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bed4301203e3, replyNumber=0, likeNumber=69, createdTime=2022-07-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bed4301203e3, moduleTitle=FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bed4301203e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839966, encodeId=faf81839966fb, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Igalmi治疗精神分裂症或双相障碍, objectType=article, longId=723944, objectId=b606e23944ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b606e23944ae, replyNumber=0, likeNumber=91, createdTime=2022-04-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b606e23944ae, moduleTitle=FDA批准Igalmi治疗精神分裂症或双相障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b606e23944ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839948, encodeId=e59d1839948ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=新药进展 | 每两个月注射1次！FDA批准长效HIV暴露前预防用药, objectType=article, longId=292876, objectId=6b3f2928e676, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b3f2928e676, replyNumber=0, likeNumber=72, createdTime=2022-09-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b3f2928e676, moduleTitle=新药进展 | 每两个月注射1次！FDA批准长效HIV暴露前预防用药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b3f2928e676)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839961, encodeId=f08a183996110, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准骨髓纤维化新药pacritinib, objectType=article, longId=301202, objectId=0b54301202e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b54301202e6, replyNumber=0, likeNumber=79, createdTime=2022-12-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b54301202e6, moduleTitle=FDA批准骨髓纤维化新药pacritinib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b54301202e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839933, encodeId=345518399335f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验, objectType=article, longId=215703, objectId=edd2215e036a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edd2215e036a, replyNumber=0, likeNumber=149, createdTime=2021-12-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edd2215e036a, moduleTitle=Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edd2215e036a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839965, encodeId=64a018399653c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, objectType=article, longId=723516, objectId=7576e23516c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7576e23516c3, replyNumber=0, likeNumber=65, createdTime=2022-08-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7576e23516c3, moduleTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7576e23516c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839959, encodeId=f9eb1839959b8, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准GABA受体别构调节剂ganaxolone上市, objectType=article, longId=301198, objectId=1aa8301198e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aa8301198e8, replyNumber=0, likeNumber=85, createdTime=2022-07-29, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aa8301198e8, moduleTitle=FDA批准GABA受体别构调节剂ganaxolone上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aa8301198e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839944, encodeId=665a183994466, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Leqvio作为一种附加疗法，以帮助降低某些高危成人的胆固醇水平, objectType=article, longId=292600, objectId=a193292600d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a193292600d9, replyNumber=0, likeNumber=65, createdTime=2022-07-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a193292600d9, moduleTitle=FDA批准Leqvio作为一种附加疗法，以帮助降低某些高危成人的胆固醇水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a193292600d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839943, encodeId=5d75183994318, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2021年12月2日简报：美国FDA批准莫努匹拉韦用于中轻度新冠治疗，奥密克戎蔓延至全球23个国家和地区；我国还有约20%的老年人未接种新冠疫苗, objectType=article, longId=221431, objectId=f1b8221431dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1b8221431dd, replyNumber=0, likeNumber=88, createdTime=2022-06-03, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1b8221431dd, moduleTitle=2021年12月2日简报：美国FDA批准莫努匹拉韦用于中轻度新冠治疗，奥密克戎蔓延至全球23个国家和地区；我国还有约20%的老年人未接种新冠疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1b8221431dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839932, encodeId=074a1839932b7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=2021年上半年盘点：FDA批准抗肿瘤药物汇总, objectType=article, longId=213749, objectId=b40b213e49de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b213e49de, replyNumber=0, likeNumber=92, createdTime=2022-05-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b213e49de, moduleTitle=2021年上半年盘点：FDA批准抗肿瘤药物汇总, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40b213e49de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839937, encodeId=f521183993e24, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Incyte的Opzelura用于治疗特应性皮炎, objectType=article, longId=217671, objectId=2e0921e67161, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e0921e67161, replyNumber=0, likeNumber=62, createdTime=2021-10-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e0921e67161, moduleTitle=FDA批准Incyte的Opzelura用于治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e0921e67161)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839914, encodeId=8f75183991465, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准PANZYGA治疗成人慢性炎性脱髓鞘性多发性神经病（CIDP）, objectType=article, longId=207131, objectId=e94620e13106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e94620e13106, replyNumber=0, likeNumber=71, createdTime=2021-07-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e94620e13106, moduleTitle=美国FDA批准PANZYGA治疗成人慢性炎性脱髓鞘性多发性神经病（CIDP）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e94620e13106)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839947, encodeId=8926183994e20, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……, objectType=article, longId=292887, objectId=627029288e90, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627029288e90, replyNumber=0, likeNumber=84, createdTime=2022-11-07, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627029288e90, moduleTitle=今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=627029288e90)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839922, encodeId=7ec718399224a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准KIMYRSA（奥利万星）用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）, objectType=article, longId=208489, objectId=6961208489ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6961208489ee, replyNumber=0, likeNumber=70, createdTime=2021-03-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6961208489ee, moduleTitle=FDA批准KIMYRSA（奥利万星）用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6961208489ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839920, encodeId=0ebd183992029, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, objectType=article, longId=208126, objectId=a66d208126c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66d208126c5, replyNumber=0, likeNumber=87, createdTime=2021-11-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66d208126c5, moduleTitle=优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66d208126c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839936, encodeId=72ab18399367c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=内幕消息 - 美国FDA批准百济神州:百悦泽用于治疗华氏巨球蛋白血症患者, objectType=article, longId=216612, objectId=93a521661262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a521661262, replyNumber=0, likeNumber=65, createdTime=2022-03-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a521661262, moduleTitle=内幕消息 - 美国FDA批准百济神州:百悦泽用于治疗华氏巨球蛋白血症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a521661262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839900, encodeId=fed71839900d2, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌, objectType=article, longId=204709, objectId=0a77204e09af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a77204e09af, replyNumber=0, likeNumber=65, createdTime=2021-02-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a77204e09af, moduleTitle=FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a77204e09af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839939, encodeId=462618399392b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Keytruda用于一线治疗宫颈癌, objectType=article, longId=218691, objectId=f3d32186914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3d32186914b, replyNumber=0, likeNumber=82, createdTime=2022-04-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3d32186914b, moduleTitle=FDA批准Keytruda用于一线治疗宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3d32186914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839899, encodeId=788a183989962, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病, objectType=article, longId=204700, objectId=ab45204e0089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab45204e0089, replyNumber=0, likeNumber=83, createdTime=2021-10-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab45204e0089, moduleTitle=FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab45204e0089)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

新药进展 | 辉瑞口服新冠特效药Paxlovid获FDA批准，预防死亡效力高达89%

2022-06-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Releuko(filgrastim-ayow) ，第三种非格司亭生物仿制药

2022-07-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Igalmi治疗精神分裂症或双相障碍

2022-04-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

新药进展 | 每两个月注射1次！FDA批准长效HIV暴露前预防用药

2022-09-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准骨髓纤维化新药pacritinib

2022-12-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Immune-Onc靶向LILRB2（ILT4）全新抑制性抗体IO-108获FDA批准将在晚期实体瘤中开展人体临床试验

2021-12-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤

2022-08-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准GABA受体别构调节剂ganaxolone上市

2022-07-29

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Leqvio作为一种附加疗法，以帮助降低某些高危成人的胆固醇水平

2022-07-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2021年12月2日简报：美国FDA批准莫努匹拉韦用于中轻度新冠治疗，奥密克戎蔓延至全球23个国家和地区；我国还有约20%的老年人未接种新冠疫苗

2022-06-03

bugit (审核中...)

前往app查看评论内容

#FDA批准#

2021年上半年盘点：FDA批准抗肿瘤药物汇总

2022-05-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Incyte的Opzelura用于治疗特应性皮炎

2021-10-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准PANZYGA治疗成人慢性炎性脱髓鞘性多发性神经病（CIDP）

2021-07-10

bugit (审核中...)

前往app查看评论内容

#FDA批准#

今日探报 | 诺华长效降脂siRNA疗法获FDA批准上市；研究表明，利用一滴血或许就能快速检测出早期肺癌……

2022-11-07

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准KIMYRSA（奥利万星）用于治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）

2021-03-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

优效于克唑替尼，FDA批准劳拉替尼一线治疗ALK阳性)阳性非小细胞肺癌(NSCLC)患者

2021-11-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

内幕消息 - 美国FDA批准百济神州:百悦泽用于治疗华氏巨球蛋白血症患者

2022-03-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准口服GnRH受体拮抗剂Orgovyx治疗晚期前列腺癌

2021-02-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Keytruda用于一线治疗宫颈癌

2022-04-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准武田的ICLUSIG（ponatinib）治疗耐药或不耐药的慢性粒细胞白血病

2021-10-04

科室
- - 订阅+
  - 更多科室
工具
服务